These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11720830)

  • 1. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.
    Vehmanen L; Saarto T; Elomaa I; Mäkelä P; Välimäki M; Blomqvist C
    Eur J Cancer; 2001 Dec; 37(18):2373-8. PubMed ID: 11720830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.
    Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
    J Clin Oncol; 1997 Apr; 15(4):1341-7. PubMed ID: 9193325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
    Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W
    Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure.
    Vehmanen L; Saarto T; Risteli J; Risteli L; Blomqvist C; Elomaa I
    Breast Cancer Res Treat; 2004 Sep; 87(2):181-8. PubMed ID: 15377842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study.
    Saarto T; Taube T; Blomqvist C; Vehmanen L; Elomaa I
    Calcif Tissue Int; 2005 Aug; 77(2):84-90. PubMed ID: 16075363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
    Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
    Br J Cancer; 1997; 75(4):602-5. PubMed ID: 9052418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy.
    Vehmanen LK; Elomaa I; Blomqvist CP; Saarto T
    Acta Oncol; 2014 Jan; 53(1):75-9. PubMed ID: 23713891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.
    Powles TJ; McCloskey E; Paterson AH; Ashley S; Tidy VA; Nevantaus A; Rosenqvist K; Kanis J
    J Natl Cancer Inst; 1998 May; 90(9):704-8. PubMed ID: 9586668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
    Vehmanen L; Elomaa I; Blomqvist C; Saarto T
    J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer.
    Rizzoli R; Forni M; Schaad MA; Slosman DO; Sappino AP; Garcia J; Bonjour JP
    Bone; 1996 Jun; 18(6):531-7. PubMed ID: 8805993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostication of hematotoxicity for radio- and chemotherapy in patients with breast cancer].
    Ivanov SD; Iamshanov VA; Korytova LI; Khazova TV; Arzumanov AS
    Vopr Onkol; 2003; 49(5):601-7. PubMed ID: 14682132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.
    Bruning PF; Pit MJ; de Jong-Bakker M; van den Ende A; Hart A; van Enk A
    Br J Cancer; 1990 Feb; 61(2):308-10. PubMed ID: 2310683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
    Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
    Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?
    Cameron DA; Douglas S; Brown JE; Anderson RA
    Breast Cancer Res Treat; 2010 Oct; 123(3):805-14. PubMed ID: 20686833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
    Gordon AM; Hurwitz S; Shapiro CL; LeBoff MS
    Menopause; 2011 Nov; 18(11):1244-8. PubMed ID: 21814159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer.
    Oostra DR; Lustberg MB; Reinbolt RE; Pan X; Wesolowski R; Shapiro CL
    Mol Cell Endocrinol; 2015 Feb; 402():51-6. PubMed ID: 25575458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
    Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
    Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer.
    McCloskey E; Paterson A; Kanis J; Tähtelä R; Powles T
    Eur J Cancer; 2010 Feb; 46(3):558-65. PubMed ID: 20031392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.